BioCryst Pharmaceuticals

BCRX

Market cap $1.43B

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX ) M&A Call October 14, 2025 8:00 AM EDT Company Participants Nick Wilder Jon Stonehouse - CEO & Executive Director Charles Gayer - President & Chief Commercial Officer Babar Ghias - CFO & Head of Corporate Development Conference Call Participants Stacy Ku - TD Cowen, Research Division Laura Chico - Wedbush Securities Inc., Research Division Steven Seedhouse - Cantor Fitzgerald & Co., Research Division Brian Abrahams - RBC Capital Markets, Research Division Jonathan Wolleben - Citizens JMP Securities, LLC, Research Division Huidong Wang - Barclays Bank PLC, Research Division Maurice Raycroft - Jefferies LLC, Research Division John Todaro - Needham & Company, LLC, Research Division Jessica Fye - JPMorgan Chase & Co, Research Division Presentation Operator Good day, and welcome to the BioCryst Pharmaceuticals Conference Call. [Operator Instructions] Please note this event is being recorded.

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) on Tuesday agreed to acquire Astria Therapeutics, Inc. (NASDAQ:ATXS) for a mix of cash and stock.

Investors need to pay close attention to BCRX stock based on the movements in the options market lately.

BioCryst Pharmaceuticals said on Tuesday it would buy Astria Therapeutics in a cash-and-stock deal valued at about $700 million, as it looks to expand its portfolio of treatments for rare diseases.

RESEARCH TRIANGLE PARK, N.C., & BOSTON--(BUSINESS WIRE)--BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) and Astria Therapeutics, Inc. (Nasdaq: ATXS) today announced that the companies have entered into a definitive agreement under which BioCryst has agreed to acquire Astria, a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, for a mix of cash and stock representing an implied value of $13.00 per Astria share, and approximately $700 mi.

– Deal to add navenibart, a late-stage and long-acting plasma kallikrein inhibitor, in Phase 3 clinical development, to BioCryst's HAE portfolio –

BioCryst (BCRX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

RESEARCH TRIANGLE PARK, N.C., Oct. 03, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted eight newly-hired employees stock options to purchase an aggregate of 115,000 shares, and restricted stock units (RSUs) covering an aggregate of 91,450 shares, of BioCryst common stock. The options and RSUs were granted as of October 1, 2025, as inducements material to each employee entering into employment with BioCryst. The options and RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4).

– Transaction valued at $250 million, with up to $14 million in future milestones – – BioCryst will focus on driving ORLADEYO sales in the U.S. while Neopharmed Gentili will lead commercialization across Europe – – Provides a significant and immediate improvement to BioCryst's operating margin – RESEARCH TRIANGLE PARK, N.C., Oct. 01, 2025 (GLOBE NEWSWIRE) --  BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that it has successfully completed the previously announced sale of its European ORLADEYO business to Neopharmed Gentili.

BioCryst Pharmaceuticals (BCRX) is highlighted for its strong potential, driven by its approved therapy ORLADEYO. BCRX's investment thesis centers on its below fair value market cap given ORLADEYO's clear path to blockbuster revenues.. Despite concerns over product concentration, BCRX is rated as a 'Buy' due to the proven efficacy and growth prospects of ORLADEYO.